Loss of basal forebrain p75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease

Journal of Comparative Neurology

Volumn 443, Issue 2, 2002, Pages 136-153

  Mufson, Elliott J ^a,b   Ma, Shuang Y ^a,b   Dills, John ^a   Cochran, Elizabeth J ^a,b   Leurgans, Sue ^a   Wuu, Joanne ^a   Bennett, David A ^a,b   Jaffar, Syed ^a   Gilmor, Michelle L ^c   Levey, Alan I ^c   Kordower, Jeffrey H ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cholinergic; Dementia; Neurotrophin receptor; Nucleus basalis; Stereology

Indexed keywords

CHOLINE ACETYLTRANSFERASE; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR; PROTEIN P75;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING AFFINITY; BRAIN DEGENERATION; CELL COUNT; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FOREBRAIN; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NERVE CELL DEGENERATION; OLIVARY NUCLEUS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; STEREOMETRY;

ACETYLCHOLINE; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BASAL NUCLEUS OF MEYNERT; CAUSALITY; CELL COUNT; COGNITION DISORDERS; DOWN-REGULATION; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; NEUROPSYCHOLOGICAL TESTS; RECEPTOR, NERVE GROWTH FACTOR; SENILE PLAQUES;

EID: 0037016848     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.10122     Document Type: Article

References (123)

1. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease
2. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype
3. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease
4. The cholinergic hypothesis of geriatric memory dysfunction
5. Around the WORLD backward: An algorithm for scoring the MMSE WORLD item
6. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale
7. Dimensionality of parkinsonian signs in aging and Alzheimer's disease
8. Visuospatial judgment: A clinical test
9. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits
10. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease
11. Keeping track of neurotrophin receptors
12. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients
13. Neuropathological staging of Alzheimer's-related changes
14. Neurotrophic agents may exacerbate the pathologic cascade of Alzheimer's disease
15. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
16. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: Prevention by NGF and bFGF
17. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and early Alzheimer's disease
18. Severe panencephalic Pick's disease with Alzheimer's disease-like neuropil threads and synaptophysin immunoreactivity
19. Application of the NIA/Reagan Institute working criteria for the diagnosis of Alzheimer's disease to members of the Religious Orders Study
20. Methods for determining numbers of cells and synapses: A case for more uniform standards of review
21. Trk receptor alterations in Alzheimer's disease
22. Incidental and intentional recall in Parkinson's disease: An account based on diminished attentional resources
23. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease
24. Selective loss of central cholinergic neurons in Alzheimer's disease
25. Cholinergic markers in elderly patients with early signs of Alzheimer disease
26. Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological and cognitive correlations
27. Analysis of choline acetyltransferase activity in cortex of individuals with mild cognitive impairment and Alzheimer's disease
28. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment
29. Questionable dementia: Clinical course and predictors of outcome
30. Cognitive impairment without dementia in older people: Prevalance, risk factor, impact on disability: The Italian longitudinal study on aging
31. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys
32. Cholinergic neurons of the nucleus basalis express elevated levels of nerve growth factor receptor mRNA in senile dementia of the Alzheimer's type
33. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease
34. Mild cognitive impairment in the elderly: Predictors of dementia
35. Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician
36. Neurotrophins induce death of hippocampal neurons via the p75 receptor
37. In situ hybridization detection of trkA mRNA in brain: Distribution, colocalization with p75NGFR and up-regulation by nerve growth factor
38. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease
39. Interrater reliability of the NIH stroke scale
40. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
41. The new stereological tools: Dissector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis
42. A serotonin-like immunoreactive fiber system in the dorsal columns of the spinal cord
43. Is Alzheimer's disease caused by a lack of nerve growth factor?
44. The time course of nerve growth factor content in different neuropsychiatric diseases: A unifying hypothesis
45. NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease
46. Evidence for early vulnerability of the medical and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques
47. Human orbitofrontal cortex: Cytoarchitecture and quantitative immunohistochemical parcellation
48. TrkA expression in the CNS: Evidence for the existence of several novel NGF-responsive CNS neurons
49. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease
50. Nerve growth factor mediates signal transduction through trk homodimer receptors
51. Signal transduction by the neurotrophin receptors
52. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques
53. Nerve growth factor immunoreactivity in the non-human primate (Cebus apella): Distribution, morphology and colocalization with cholinergic enzymes
54. Nerve growth factor receptor and choline acetyltransferase remain colocalized in the nucleus basalis (Ch4) of Alzheimer's patients
55. Trk-immunoreactivity in the monkey central nervous system: Forebrain
56. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment
57. Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease
58. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts
59. Dopamine transporter immunoreactive neurons decrease with age in the human substantia nigra
60. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain
61. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
62. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase
63. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia Innominata), and hypothalamus in the Rhesus monkey
64. Mild cognitive impairment: Further caution
65. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
66. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease
67. Mild cognitive impairment represents early-stage Alzheimer's Disease
68. Do psychological risk factors contribute to Alzheimer's disease?
69. Nerve growth factor and its receptors in the primate forebrain: Alterations in Alzheimer's disease and potential use in experimental therapeutics
70. Nerve growth factor in Alzheimer's disease
71. Cholinergic basal forebrain systems in the primate central nervous system: Anatomy, connectivity, neurochemistry, aging, dementia and experimental therapeutics
72. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across sub regions of the basal forebrain
73. Nerve growth factor-like immunoreactive profiles in the primate basal forebrain and hippocampal formation
74. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis
75. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease
76. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease
77. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment
78. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease
79. Consensus recommendations for the postmortem diagnosis of AD
80. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with unbiased stereological method
81. The cholinergic system in old age and Alzheimer's disease
82. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
83. Mild cognitive impairment: Clinical characterization and outcome
84. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis
85. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
86. Apolipoprotein E4 allele as a predictor of cholinergic deficits a treatment outcome in Alzheimer's disease
87. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease
88. Induction of apoptosis by the low-affinity NGF receptor
89. An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons
90. The predictive value of APOE genotyping in the elderly diagnosis of dementia of the Alzheimer's type: Data from three independent series
91. Very mild senile dementia of the Alzheimer type. I. Clinical assessment
92. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy
93. Colocalization of high affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease
94. A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer's disease
95. P75 neurotrophin receptor in the nucleus basalis of Meynert in relation to age, sex, and Alzheimer's disease
96. Evolution of Alzheimer's disease-related cytoskelatal changes in the basal nucleus of Meynert
97. Expression of NGF receptor in the developing and adult primate central nervous system
98. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis
99. Reduction in trkA immunoreactive neurons is not associated with an overexpression ofgalaninergic fibers within the nucleus basalis in Down's syndrome
100. Presynaptic cholinergic dysfunction in patients with dementia
101. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life
102. TrkA-immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin
103. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele
104. Influence of education and occupation on the incidence of Alzheimer's disease
105. Neuronal counts in the nucleus of Meynert in Alzheimer's disease and in simple senile dementia
106. Dementia: A brief and selective review
107. The decline in synapses and cholinergic activity is asynchronous in Alzheime's disease
108. Cognitive functions of the basal forebrain cholinergic system in monkeys: Memory or attention?
109. Detection and staging of dementia in Alzheimer's disease: Use of the neuropsychological measures developed for CERAD
110. New stereological methods for counting neurons
111. Estimation of the number of somatostatin neurons in the striatum: An in situ hybridization study using the optical fractionator method
112. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
113. Plaques, tangles and dementiaA quantitative study
114. Estimating WAIS-R IQ from the National Adult Reading Test: A cross-validation
115. Change in cognitive function among older persons from a community population: Relation to age and Alzheimer's disease
116. Clinical potential of growth factors in neurological disorders